AIMOVIG® (erenumab) prescribing information (external link)
KESIMPTA®▼ (ofatumumab) prescribing information (external link)
MAYZENT® (siponimod) prescribing information (external link)
This page includes promotional content created and funded by Novartis Pharmaceuticals UK Ltd. Novartis products may be mentioned.
Neuroscience
AIMOVIG® (erenumab)
KESIMPTA®▼ (ofatumumab)
Video
3 mins 8 secs
Patient journey: How KesimptaConnect can support your patients
Video
3 mins 51 secs
Patient “Voice”: Perspectives on KesimptaConnect
Video
5 mins 6 secs
HCP interviews: KesimptaConnect Real World Experience
MAYZENT® (siponimod)
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
